Raised Serum Vascular Endothelial Growth Factor Levels Are Associated with Destructive Change in Inflammatory Arthritis

Arthritis and Rheumatism

Volumn 44, Issue 9, 2001, Pages 2055-2064

  Ballara, Sundeept ^a   Taylor, Peter C ^a   Reusch, Petra ^b   Marmé, Dieter ^b   Feldmann, Marc ^a   Maini, Ravinder N ^a   Paleolog, Ewa M ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b TUMOR BIOLOGY CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; SCLEROPROTEIN; VASCULOTROPIN; VASCULOTROPIN A;

ACUTE PHASE RESPONSE; ADULT; AGED; ARTICLE; BLOOD; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SOLUBILITY; SYNOVIUM; VASCULARIZATION;

ACUTE-PHASE REACTION; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; DISEASE PROGRESSION; ENDOTHELIAL GROWTH FACTORS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOKINES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SOLUBILITY; SYNOVIAL MEMBRANE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035460227     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200109)44:9<2055::AID-ART355>3.0.CO;2-2     Document Type: Article

References (34)

1. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-10.
2. Ballara SC, Miotla JM, Paleolog EM. New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders. Int J Exp Pathol 1999;80:235-50.
3. Walsh DA. Angiogenesis and arthritis. Rheumatology (Oxford) 1999;38:103-12.
4. Paleolog EM, Fava RA. Angiogenesis in rheumatoid arthritis: implications for future therapeutic strategies. Springer Semin Immunopathol 1998;20:73-94.
5. Koch AE. Angiogenesis: implications for rheumatoid arthritis [review]. Arthritis Rheum 1998;41:951-62.
6. Paleolog EM, Miotla JM. Angiogenesis in arthritis: role in disease pathogenesis and as a potential therapeutic target. Angiogenesis 1998;2:295-307.
7. Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997;79: 233-69.
8. Achen MG, Stacker SA. The vascular endothelial growth factor family: proteins which guide the development of the vasculature. Int J Exp Pathol 1998;79:255-65.
9. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
10. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-5.
11. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994;180:341-6.
12. Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL, et al. Vascular endothelial growth factor: a cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994;152:4149-56.
13. Harada M, Mitsuyama K, Yoshida H, Sakisaka S, Taniguchi E, Kawaguchi T, et al. Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 1998;27:377-80.
14. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998;41:1258-65.
15. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, Flt-1, and its heterodimerization with KDR. Biochcm Biophys Res Commun 1996;226:324-8.
16. Hornig C, Weich HA. Soluble VEGF receptors: recombinant and naturally occurring forms involved in the regulation of angiogenesis. Angiogenesis 1999;3:33-9.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
18. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
19. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 1990;33:1601-10.
20. Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991;34:505-14.
21. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
22. Van der Heijde DM, van't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-81.
23. Prevoo MLL, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
24. Van Gestel AM, Prevoo MLL, van't Hof MA, van Rijswijk MH, van de Putte LBA, van Riel PLCM. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40.
25. Van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27:261-3.
26. Barleon B, Siemeister G, Martiny-Baron G, Weindel K, Herzog C, Marme D. Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (Flt-1) and a soluble variant of Flt-1 in human vascular endothelial cells. Cancer Res 1997;57: 5421-5.
27. Paleolog EM. Angiogenesis: a critical process in the pathogenesis of RA - a role for VEGF? Br J Rheumatol 1996;35:917-9.
28. Mohle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A 1997;94:663-8.
29. Nagashima M, Wauke K, Hirano D, Ishigami S, Aono H, Takai M, et al. Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis. Rheumatology (Oxford) 2000;39:1255-62.
30. Kikuchi K, Kubo M, Kadono T, Yazawa N, Ihn H, Tamaki K. Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol 1998;139:1049-51.
31. Van der Heijde DM, van Leeuwen MA, van Riel PL, van de Putte LB. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol 1995;22:1792-6.
32. Hulsmans HMJ, Jacobs JWG, van der Heijde DMFM, van Albada-Kuipers GA, Schenk Y, Bijlsma JWJ. The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum 2000;43:1927-40.
33. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999;163:1521-8.
34. Miotla JM, Maciewicz R, Kendrew J, Feldmann M, Paleolog E. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest 2000:80:1195-205.